Zasocitinib Medicine 04 December 2025 Extended indication Zasocitinib monotherapy for treatment of moderate to severe Plaque psoriasis in adults and elderly who are candidates for phototherapy or systemic therapy. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Zasocitinib Domain Chronic immune diseases Reason of inclusion New medicine (specialité) Main indication Skin diseases Extended indication Zasocitinib monotherapy for treatment of moderate to severe Plaque psoriasis in adults and elderly who are candidates for phototherapy or systemic therapy. Current proprietary name Already available biosimilars / generics Proprietary name unknown Manufacturer Takeda Portfolio holder Takeda Mechanism of action Tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP Submission date July 2026 Expected Registration September 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks NCT06088043 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Richtlijn Psoriasis NVDV (2023); Menter et al., JAAD (2020); CBS bevolkingsdata. Additional remarks Psoriasis komt voor bij circa 2 tot 3% van de Nederlandse bevolking (ongeveer 350.000 tot 500.000 mensen). Hiervan heeft naar schatting 25 tot 30% matige tot ernstige plaque psoriasis, wat overeenkomt met 90.000 tot 150.000 patiënten die in aanmerking komen voor systemische therapie. Afhankelijk van effectiviteit en vergoeding zou zasocitinib bij markttoetreding mogelijk worden gebruikt door 10.000 tot 30.000 patiënten per jaar. Expected cost per patient per year Cost € 8,100.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks Kosten op basis van IHSI-inschatting, afgeleid van de mediane kosten van dezelfde ATC-klasse (L04AF - JAK inhibitors) geneesmiddelen in Nederland. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks